XORTX Therapeutics (XRTX) Non-Current Assets (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Non-Current Assets came in at $1.4 million in Q1 2026, little changed YoY from $1.4 million in Q1 2025, and down 1.55% on a QoQ basis from $1.4 million in Q4 2025.
XORTX Therapeutics (XRTX) Non-Current Assets (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Non-Current Assets data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Non-Current Assets changed 0.37% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 1.02% YoY) and the FY2025 annual result came in at $1.4 million, changed 0.32% from the prior year.
- Non-Current Assets slipped to $1.4 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.5 million in Q2 2025 to a low of $1.4 million in Q1 2024.
- A 5-year average of $1.4 million and a median of $1.4 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets slipped 5.16% — and 2025, when it climbed 2.41%.
- Tracing XRTX's Non-Current Assets over 5 years: stood at $1.5 million in 2022, then retreated by 5.16% to $1.4 million in 2023, then increased by 1.33% to $1.4 million in 2024, then increased by 0.32% to $1.4 million in 2025, then dropped by 1.55% to $1.4 million in 2026.
- The last three Non-Current Assets figures came in at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 18.06 Bn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.40 Mn |
| Dec 31, 2025 | 1.42 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 1.41 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Dec 31, 2022 | 1.48 Mn |
| Dec 31, 2021 | 1.48 Mn |
| Dec 31, 2020 | 179,733.18 |